Ancillary Benefit of Increased HPV Immunization Rates Following a CBPR Approach to Address Immunization Disparities in Younger Siblings.
Adolescent
Child, Preschool
Community-Based Participatory Research
Community-Institutional Relations
Female
Health Education
/ organization & administration
Health Status Disparities
Humans
Immunization Programs
/ organization & administration
Infant
Male
Papillomavirus Infections
/ prevention & control
Papillomavirus Vaccines
/ administration & dosage
Parents
/ education
Siblings
Socioeconomic Factors
Vaccination Coverage
/ statistics & numerical data
Wisconsin
Adolescents
Community-based participatory research (CBPR)
Health disparities
Human papilloma virus (HPV)
Immunizations
Journal
Journal of community health
ISSN: 1573-3610
Titre abrégé: J Community Health
Pays: Netherlands
ID NLM: 7600747
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
4
1
2019
medline:
17
6
2020
entrez:
4
1
2019
Statut:
ppublish
Résumé
Increasing HPV vaccination rates may decrease the disproportionately high HPV-associated disease incidence and mortality in African Americans (AA) and lower socioeconomic individuals. Data from a community-based participatory research (CBPR) study addressing immunization disparities among 19-35 month old children was analyzed to identify ancillary benefits in HPV immunization rates for adolescent siblings. Sub-study analysis inclusion criteria: AA (N = 118), 13-17 years old, younger sibling enrolled in parent study, and enrolled ≥ 9 months. Parent/caregiver interventions included: a web-based immunization toolkit with information on age-appropriate vaccines; a multimedia community outreach campaign; and reminder mailings. HPV up-to-date (UTD) status was defined as Wisconsin Immunization Registry (WIR) documentation of at least three HPV vaccines. McNemar's test compared pre/post intervention HPV status. Two dependent proportions testing compared the proportion of adolescents that became UTD in the study cohort, City of Milwaukee, and State of Wisconsin. Parents/caregivers perceived that 92% of adolescents were HPV-UTD, while only 24% had a WIR-verified HPV-UTD status. Baseline UTD status of the younger siblings 19-35 month old 4:3:1:3:3:1:4 antigen series was 63%, which increased to 86% at study completion. Adolescent's HPV-UTD immunization status increased from 30 (25%) at enrollment to 54 (46%) at study completion [p = 0.004]. A statistically significant larger proportion of adolescents became HPV-UTD in the study cohort (20%) compared to the City of Milwaukee [14%, p = 0.042] and the State of Wisconsin [14%, p = 0.046]. A culturally-tailored CBPR approach targeting parents/caregivers of younger AA children can have significant ancillary benefit to increase HPV immunization rates in adolescent siblings.
Identifiants
pubmed: 30604221
doi: 10.1007/s10900-018-00610-9
pii: 10.1007/s10900-018-00610-9
pmc: PMC6504598
mid: NIHMS1517787
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
544-551Subventions
Organisme : NIMHD NIH HHS
ID : R24 MD001812
Pays : United States
Références
Environ Health Perspect. 2002 Apr;110 Suppl 2:155-9
pubmed: 11929724
Am J Public Health. 2003 Aug;93(8):1210-3
pubmed: 12893597
J Contin Educ Health Prof. 2006 Winter;26(1):13-24
pubmed: 16557505
J Health Commun. 2006;11 Suppl 1:1-17
pubmed: 16641071
Health Promot Pract. 2006 Jul;7(3 Suppl):191S-200S
pubmed: 16760249
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24
pubmed: 17380109
J S C Med Assoc. 2009 Dec;105(7):309-17
pubmed: 20108724
MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8
pubmed: 22189893
J Natl Cancer Inst. 2013 Feb 6;105(3):158-61
pubmed: 23297040
Sex Transm Dis. 2013 Mar;40(3):187-93
pubmed: 23403598
Int Q Community Health Educ. 2012-2013;33(1):39-53
pubmed: 23570827
Hum Vaccin Immunother. 2013 Jul;9(7):1413-20
pubmed: 23571170
J Adolesc Health. 2013 Dec;53(6):756-62
pubmed: 23992645
Vaccine. 2014 Apr 7;32(17):1901-20
pubmed: 24530401
MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30
pubmed: 25167164
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4
pubmed: 25811679
WMJ. 2015 Feb;114(1):10-5
pubmed: 25845130
JAMA Pediatr. 2015 Jul;169(7):686-92
pubmed: 26010507
Prog Community Health Partnersh. 2016 Spring;10(1):19-30
pubmed: 27018351
MMWR Morb Mortal Wkly Rep. 2016 Jul 08;65(26):661-6
pubmed: 27387669
Cancer Epidemiol Biomarkers Prev. 2016 Oct;25(10):1435-1446
pubmed: 27486020
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):850-8
pubmed: 27561081
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408
pubmed: 27977643
NCHS Data Brief. 2017 Apr;(280):1-8
pubmed: 28463105
Papillomavirus Res. 2017 Jun;3:42-45
pubmed: 28720455
Vaccine. 2017 Oct 27;35(45):6122-6128
pubmed: 28958810